Orakl Oncology raises $34M to predict cancer drug results with AI

First reported by The Next Web at · Updated · 1 source

Paris-based Orakl Oncology has raised a $34M Series A co-led by Norrsken VC and Singular. It grows copies of patients’ tumours in the lab, tests drugs on them and uses AI to predict trial results.

Reported so far by one publisher.

Summary from The Next Web.

Reporting1

The Next Web Orakl Oncology raises $34M to predict cancer drug results with AI · Ana-Maria Stanciuc

Related